Amgen TEPEZZA Subcutaneous Trial Shows Strong Phase 3 Results
Thousand Oaks, California, USA, April 6, 2026 Phase 3 Success Expands TEPEZZA Treatment Options In a major advancement for...
Subcutaneous Injection
Advertisement
Sanofi Sarclisa SC Wins CHMP Nod for Myeloma Care
Paris, France | March 27, 2026 CHMP Recommends Innovative Subcutaneous Formulation Sanofi has achieved a major regulatory milestone as...
FDA Accepts LEQEMBI sBLA, Expanding At-Home Alzheimer’s Therapy
Tokyo & Cambridge, Massachusetts, January 25, 2026 — Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food...
Glenmark Launches Phase 3 Global Study of Envafolimab for Lung Cancer
MUMBAI, India, September 5, 2025 — Glenmark Pharmaceuticals has announced the initiation of a multi-country Phase 3 clinical trial...
FDA Approves LEQEMBI IQLIK Subcutaneous Autoinjector for Maintenance Dosing in Early Alzheimer’s Disease
Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved LEQEMBI®...
Advertisement
